2021 TSOC Expert Consensus on the Clinical Features, Diagnosis, and Clinical Management of Cardiac Manifestations of Fabry Disease
Authors:
- 1 July 2021
- journal article
- review article
- Vol. 37 (4) , 337-354
Abstract
Fabry disease (FD) is an X-linked, rare inherited lysosomal storage disease caused by alpha-galactosidase A gene variants resulting in deficient or undetectable alpha-galactosidase A enzyme activity. Progressive accumulation of pathogenic globotriaosylceramide and its deacylated form globotriaosylsphingosine in multiple cell types and organs is proposed as main pathophysiology of FD, with elicited pro-inflammatory cascade as alternative key pathological process. The clinical manifestations may present with either early onset and multisystemic involvement (cutaneous, neurological, nephrological and the cardiovascular system) with a progressive disease nature in classic phenotype, or present with a later-onset course with predominant cardiac involvement (non-classical or cardiac variant; e.g. IVS4+919G>A in Taiwan) from missense variants. In either form, cardiac involvement is featured by progressive cardiac hypertrophy, myocardial fibrosis, various arrhythmias, and heart failure known as Fabry cardiomyopathy with potential risk of sudden cardiac death. Several plasma biomarkers and advances in imaging modalities along with novel parameters, cardiac magnetic resonance (CMR: native T1/T2 mapping) for myocardial tissue characterization or echocardiographic deformations, have shown promising performance in differentiating from other etiologies of cardiomyopathy and are presumed to be helpful in assessing the extent of cardiac involvement of FD and in guiding or monitoring subsequent treatment. Early recognition from extra-cardiac red flag signs either in classic form or red flags from cardiac manifestations in cardiac variants, and awareness from multispecialty team work remains the cornerstone for timely managements and beneficial responses from therapeutic interventions (e.g. oral chaperone therapy or enzyme replacement therapy) prior to irreversible organ damage. We aim to summarize contemporary knowledge based on literature review and the gap or future perspectives in clinical practice of FD-related cardiomyopathy in an attempt to form a current expert consensus in Taiwan.Keywords
This publication has 100 references indexed in Scilit:
- Long‐term outcome of enzyme‐replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complicationsJournal of Internal Medicine, 2013
- Lyso‐globotriaosylsphingosine (lyso‐Gb3) levels in neonates and adults with the Fabry disease later‐onset GLA IVS4+919G>A mutationJournal of Inherited Metabolic Disease, 2012
- Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosisEuropean Heart Journal, 2012
- Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry DiseasePLOS ONE, 2012
- Globotriaosylsphingosine Accumulation and Not Alpha-Galactosidase-A Deficiency Causes Endothelial Dysfunction in Fabry DiseasePLOS ONE, 2012
- Fabry diseaseOrphanet Journal of Rare Diseases, 2010
- Frequency of Unrecognized Fabry Disease Among Young European-American and African-American Men With First Ischemic StrokeStroke, 2010
- Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onsetGLAmutation c.936+919G>A (IVS4+919G>A)Human Mutation, 2009
- Myofilament Degradation and Dysfunction of Human Cardiomyocytes in Fabry DiseaseThe American Journal of Pathology, 2008
- The heart in Anderson-Fabry disease and other lysosomal storage disordersHeart, 2007